scholarly journals Appraisal of Clinical Practice Guideline: Interventions to Prevent Falls in Community-Dwelling Older Adults: U.S. Preventive Services Task Force Recommendation Statement

2019 ◽  
Vol 65 (2) ◽  
pp. 112
Author(s):  
Mark Hancock
Keyword(s):  
Older Adults ◽  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Task Force ◽  
Preventive Services ◽  
Community Dwelling ◽  
Community Dwelling Older Adults

Psychological Distress and the Use of Clinical Preventive Services by Community-Dwelling Older Adults

2017 ◽  
Vol 38 (5) ◽  
pp. 599-616 ◽  
Author(s):  
Szu-Hsuan Lin ◽  
Omolola E. Adepoju ◽  
Bita A. Kash ◽  
Bethany DeSalvo ◽  
Darcy K. McMaughan
Keyword(s):  
Breast Cancer ◽  
Older Adults ◽  
Psychological Distress ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Emotional Health ◽  
Preventive Services ◽  
Community Dwelling ◽  
Clinical Preventive Services ◽  
Community Dwelling Older Adults

In this study, we explored whether psychological distress plays a role in the use of recommended clinical preventive services among community-dwelling older adults. The sample is drawn from respondents 65 years and older who participated in the 2011 Medical Expenditure Panel Survey (MEPS). Logistic regressions with selected covariates were entered in the model to estimate odds ratios (OR) with 95% confidence interval (CI) for the independent effect of psychological distress on the utilization of each of five preventive services. With the exception of breast cancer screening where the uptake of preventive services was significantly lower for older adults with psychological distress (OR = 0.57, p < .001), uptake of other key preventive measures revealed no significant utilization differences between older adults with and without psychological distress. The results suggest that adherence to breast cancer screening guidelines may be increased by improving recognition and treatment of emotional health problems in older women.

The modified sphygmomanometer test for assessment of muscle strength of community-dwelling older adults in clinical practice: reliability and validity

2020 ◽  
pp. 1-8
Author(s):  
Sherindan Ayessa Ferreira de Brito ◽  
Marina de Melo Santana ◽  
Poliana do Amaral Benfica ◽  
Larissa Tavares Aguiar ◽  
Gisele de Cássia Gomes ◽  
...  
Keyword(s):  
Older Adults ◽  
Clinical Practice ◽  
Muscle Strength ◽  
Reliability And Validity ◽  
Community Dwelling ◽  
Community Dwelling Older Adults

scholarly journals Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline

2018 ◽  
Vol 103 (5) ◽  
pp. 1715-1744 ◽  
Author(s):  
Shalender Bhasin ◽  
Juan P Brito ◽  
Glenn R Cunningham ◽  
Frances J Hayes ◽  
Howard N Hodis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Adverse Effects ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Task Force ◽  
Specific Antigen ◽  
Androgen Deficiency ◽  
Testosterone Therapy ◽  
Endocrine Society

Abstract Objective To update the “Testosterone Therapy in Men With Androgen Deficiency Syndromes” guideline published in 2010. Participants The participants include an Endocrine Society–appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone–binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level &gt; 4 ng/mL, prostate-specific antigen &gt; 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.

scholarly journals Diabetes and Pregnancy: An Endocrine Society Clinical Practice Guideline

2013 ◽  
Vol 98 (11) ◽  
pp. 4227-4249 ◽  
Author(s):  
Ian Blumer ◽  
Eran Hadar ◽  
David R. Hadden ◽  
Lois Jovanovič ◽  
Jorge H. Mestman ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Clinical Practice Guideline ◽  
Practice Guideline ◽  
Task Force ◽  
Evidence Based ◽  
Conference Calls ◽  
Endocrine Society ◽  
Assessment Development ◽  
Contemporary Management ◽  
Diabetes And Pregnancy

Objective: Our objective was to formulate a clinical practice guideline for the management of the pregnant woman with diabetes. Participants: The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee of The Endocrine Society, 5 additional experts, a methodologist, and a medical writer. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. Consensus Process: One group meeting, several conference calls, and innumerable e-mail communications enabled consensus for all recommendations save one with a majority decision being employed for this single exception. Conclusions: Using an evidence-based approach, this Diabetes and Pregnancy Clinical Practice Guideline addresses important clinical issues in the contemporary management of women with type 1 or type 2 diabetes preconceptionally, during pregnancy, and in the postpartum setting and in the diagnosis and management of women with gestational diabetes during and after pregnancy.

Sign in / Sign up

Export Citation Format

Share Document